Ric Lucien, President and Chief Executive Officer
Mr. Lucien joined Bal in late 2010 and brings over 27 years of experience in managing finance and operations of international companies and their subsidiaries. He has served previously as Chief Financial Officer and in operating and executive management capacities in both public and pre-public companies, including Remend, Inc., Boostworks, Inc., and Centura Software Corporation and has helped raise over $150 million in both public and private financings over the course of his career.

Dr. Alexander Chu, Chief Engineering Officer
Dr. Chu brings a wealth of diverse experience in bioprocess development and engineering scale up to Bio Architecture Lab as its Chief Engineering Officer. He has established a solid track record of commercialization of a large variety of high-value products, including monoclonal antibodies, protein therapeutics, glycopeptides and small molecules derived from chemical synthesis. He was most recently Vice President of Manufacturing and Process Development at Essentient and also, Microbia, DSM Nutritional Products. Prior to these roles, he was Vice President, Process Development and Manufacturing at Adnexus Therapeutics, a Bristol-Myers Squibb company. He has held multiple scientific and management positions at Abbott Laboratories and Abbott BioResearch Center, including Director of Manufacturing Program Management, CMC, and Director, Process Sciences, Pharma. Alex earned a bachelor's degree in chemical engineering from National Taiwan University and a Ph.D. in biochemical engineering from the University of Wisconsin-Madison.

Dr. Yasuo Yoshikuni, Co-Founder & Chief Science Officer
Dr. Yoshikuni co-founded Bio Architecture Lab and has developed the first platform technology of synthetic biology that enables the conversion of a previously untapped feedstock (seaweed) into a variety of chemicals. He currently directs BAL's core research programs and Intellectual Property efforts. Dr. Yoshikuni brings a decade of research experiences in protein engineering, computational enzyme design, and metabolic engineering into BAL. He has authored numerous publications including Nature and Chemistry & Biology. Dr. Yoshikuni completed his Ph.D. at University of California, Berkeley with Professor Jay D. Keasling. He then pursued a post-doctorate as a Howard Hughes Medical Institute and Jane Coffin Child's memorial fellow at University of Washington, Seattle with Professor David Baker.

Yuki Kashiyama, Co-founder, General Manager of Global Biomass Sourcing
Mr. Kashiyama co-founded Bio Architecture Lab after a successful career at Boston Consulting Group in its biotechnology and pharmaceuticals practice, where he received "the consultant of the year award" from BCG Japan. He currently leads BAL's global biomass sourcing operations and also leads business development in Asia. Mr. Kashiyama has extensive experience in strategy and business development and has very deep knowledge of seaweed aquafarming and sourcing businesses. He received his MBA from Haas School of Business at University of California, Berkeley and his BE from the University of Tokyo in Chemistry & Biotechnology.

Dr. Richard Bailey, Scientific Adviser
Dr. Bailey has spent approximately 35 years in the industrial biotechnology sector, having been involved in the commercialization of multiple specialty and commodity chemicals over this time span. He has participated in every phase of fermentation process development, from developing or leading the efforts for strain engineering, to managing fermentation process development and multi-disciplinary teams involved in piloting and scaling up laboratory technology. Prior to joining Bio Architecture Lab, he was CEO and Founder of Microbia, Inc., a majority owned subsidiary of Ironwood Pharmaceutical engaged in the development and commercialization of specialty chemicals in fungi. Before joining Microbia in 2002, he held senior management positions for several divisions of Monsanto with responsibilities for programs in both fermentation process development and agricultural biotechnology, and prior to joining Monsanto, he was VP of R&D for ZeaGen, a start-up biotechnology company based on Colorado.

Daniel Trunfio, Chairman
Mr. Trunfio was appointed the Chief Executive Officer of BAL in May 2010. He has over 26 years of domestic and international experience in the Oil and renewable fuels industries. Mr. Trunfio started his professional career with Royal Dutch Shell Petroleum Company in 1984 and held increasing leadership roles including Vice President and General Manager. In 2003, he led the development and implementation of Shell's 1st and 2nd generation bio-fuel strategies and operations worldwide. In this role, he was responsible for managing Shell's strategic bio-fuel Joint Ventures portfolio in the Americas as well as working as the liaison with external stakeholders and Governments. Mr. Trunfio also held a number of leadership roles in Shell's commercial, marketing, trading and supply businesses.

Immediately prior to joining BAL, Mr. Trunfio was Chief Operating Officer at Aventine Renewable Energy where he was responsible for full profit and loss (P&L) management and operational leadership of more than 300 employees, manufacturing, sales, trading, risk management, regulatory compliance, technology, and capital expansion.

Ric Lucien, President and Chief Executive Officer
Mr. Lucien joined Bal in late 2010 and brings over 27 years of experience in managing finance and operations of international companies and their subsidiaries. He has served previously as Chief Financial Officer and in operating and executive management capacities in both public and pre-public companies, including Remend, Inc., Boostworks, Inc., and Centura Software Corporation and has helped raise over $150 million in both public and private financings over the course of his career.

Yuki Kashiyama, Co-founder, General Manager, Global Biomass Sourcing
Mr. Kashiyama co-founded Bio Architecture Lab after a successful career at Boston Consulting Group in its biotechnology and pharmaceuticals practice, where he received "the consultant of the year award" from BCG Japan. He currently leads BAL's global biomass sourcing operations and also leads business development in Asia. Mr. Kashiyama has extensive experience in strategy and business development and has very deep knowledge of seaweed aquafarming and sourcing businesses. He received his MBA from Haas School of Business at University of California, Berkeley and his BE from the University of Tokyo in Chemistry & Biotechnology.

Michael Borrus, General Partner, X/Seed Capital
Michael is the founding general partner of X/Seed Capital. Prior to founding X/Seed, he was an Executive in Residence at Mohr Davidow Ventures in Silicon Valley. He is the author of books and articles on topics such as management of technology, high technology competition, and financial strategies for technology companies. He is also a frequent speaker before corporate and public audiences, and has appeared in numerous media outlets from CNN and NPR to Business Week and the New York Times. Michael serves on the Advisory Committee to the U.S. Government's Advanced Technology Program, and several National Academy of Science/National Research Council Steering Committees. He is an honors graduate of Harvard Law School, the University of California, Berkeley and Princeton University, as well as a member of the California State Bar.

Felipe Camposano, General Partner, Austral Capital
Felipe is a general partner at Austral Capital and also serves as Strategic Planning Chair for the ASEM-BIO (the Chilean Biotechnology Association). He currently holds board seats at Lucien Biotech (which he co-founded), and at the Agro Biotech Center of DICTUC, the technology transfer arm of Universidad Católica de Chile. Prior to joining Austral, Felipe directed New Business Development at Fundación Chile where he created and invested in new technology companies. Felipe was founder and CEO of INTRA, delivering enterprise knowledge management solutions to Global 1000 firms and was co-founder of NEXION, providing technology development services to Latin American companies in China. He has served as consultant and advisor at CORFO-Invest and ProChile, promoting international investment in Chile; new project valuation at OPS&S in Argentina, Brazil and Chile; and technology advisor to CORFO-Innova, the Chilean Development Agency. Filipe has taught the Technology Entrepreneur Marketing course at Universidad Católica de Chile, written the investor column at BioNexa (RedCiencia) and won national and international innovation awards for his patents (PCT/IB2007/050917). Felipe holds a BSc. in Computer Sciences and a MSc. in Industrial Engineering from Universidad Católica de Chile.

Sigurd M. Paulsen, Investment Director, Statoil ASA
Since 2007 Sigurd has been an investment director with Statoil ASA, ($75 billion market cap, NYSE/OSE listed oil & gas/renewable energy) responsible for Statoil's equity ownership positions in 35+ oil/gas/renewable technology companies. He has extensive investment and divestment experience as the previous Head of Statoil Corporate M&A as well as responsibility for Statoil's pension fund investments in private equity funds. Sigurd has been and currently is a board member of several technology start-up companies and seed funds. Sigurd has broad international work experience (Norwegian Export Council, Germany, Berliner Handels-und Frankfurter Bank, Germany, Tenneco, USA, Statoil, USA) and bachelors and masters degrees in finance and accounting from St.Gallen Switzerland.

Alex Seelenberger, Partner and Managing Director, Aurus Bios
Alex Seelenberger joined Aurus in early 2009, and is currently Partner and Managing Director of Aurus Bios, the first Chilean Life Science focused venture capital fund. He currently serves on the board of various portfolio companies, including Andes Biotechnologies, Phytotox and PLx Pharma, as well as Asembio (Chilean Biotechnology Association). Between 2007-2009, Alex worked for Athelera LLC, an M&A advisory boutique, based in New York. Prior to Athelera, from 2002 to 2005, he was a consultant for the Boston Consulting Group, where he focused primarily in the pharmaceutical, mining and financial services industries across Latin America. Alex has also lectured in several courses at the graduate and undergraduate levels at the University of Chile's Business School. Alex Seelenberger earned his Business Engineering degree from the University of Chile and an MBA with High Distinction from Harvard Business School, where he graduated as a Baker Scholar.